{
    "nct_id": "NCT03486314",
    "official_title": "A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients With Advanced Solid Tumors",
    "inclusion_criteria": "1. Adult participants who have a histologically or cytologically confirmed metastatic or locally advanced solid tumor that is appropriate for treatment with either docetaxel or carboplatin + paclitaxel in Part B of this study, or have progressed despite standard therapy, or for whom conventional therapy is not considered effective.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n3. Expected survival of at least 3 months from the date of enrollment in the study.\n4. Recovered (that is, less than or equal to (<=) Grade 1 toxicity) from the effects of prior antineoplastic therapy.\n5. Adequate organ functions (kidney, liver, cardiac, bone marrow).\n6. Suitable venous access for the study-required blood sampling (including PK sampling).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior treatment with radiation therapy involving greater than or equal to (>=) 25% of the hematopoietically active bone marrow.\n2. Life-threatening illness or serious (acute or chronic) medical or psychiatric illness unrelated to cancer.\n3. Active, uncontrolled infection or severe infectious disease.\n4. Known human immunodeficiency virus (HIV) seropositive or known hepatitis B or hepatitis C infection.\n5. With significant heart or pulmonary disease.\n6. Requiring chronic treatment with breast cancer resistance protein (BCRP) inhibitors.\n\nCriteria for Continuation into Optional Part B:\n\nTo be eligible for Part B, participants must have completed Part A and be reassessed to determine if they meet the continuation criteria for Part B.",
    "miscellaneous_criteria": ""
}